Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 71–80, page 8 of 20. Filter these by subject, year and score in the research library →

1. Disparities in Early Lecanemab Uptake Among US Medicare BeneficiariesResearch summary

   Research summaries · alzhub.org/study/disparities-in-early-lecanemab-uptake-among-us-medicare-beneficiaries-40372759

   … impairment received lecanemab and whether some groups were less likely to get it. It reports on uptake patterns only, not on whether the drug helped those patients. This cross-sectional study examines lecanemeb update among …

2. Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world studyResearch summary

   Research summaries · alzhub.org/study/effectiveness-safety-and-biomarker-dynamics-of-lecanemab-in-chinese-41823189

   Lecanemab significantly attenuated cognitive decline versus ADNI. Plasma Aβ42, Aβ40, phosphorylated tau 217 (p‑tau217), glial fibrillary acidic protein (GFAP), and ratios showed robust changes; a p‑tau217 reduction correlated …

3. Exploring the efficacy and safety of lecanemab in the management of early Alzheimer's disease: A systematic review of clinical evidenceResearch summary

   Research summaries · alzhub.org/study/exploring-the-efficacy-and-safety-of-lecanemab-in-the-management-of-40232258

   … functional impairment. Lecanemab has shown safety and efficacy in clinical trials.ObjectiveThis review aims to understand the clinical evidence of lecanemab's effectiveness and safety in managing early AD.MethodsA systematic …

4. FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-149a0541

   The FDA gave lecanemab (Leqembi) accelerated approval based on Phase 2 data showing it reduced amyloid plaque in the brain, ahead of full Phase 3 results. The label carried a warning about ARIA (amyloid-related imaging …

5. Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemabResearch summary

   Research summaries · alzhub.org/study/intracerebral-hemorrhage-following-mild-aria-h-in-an-apoe-2-carrier-39702440

   … (APOE)ε2 carrier receiving lecanemab who developed late onset intracerebral hemorrhage (ICH) following amyloid-related imaging abnormalities-hemorrhage (ARIA-H). Method We detail the history and neuroimaging findings of a …

6. Lecanemab Binds to Transgenic Mouse Model‐Derived Amyloid‐β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic FoldsResearch summary

   Research summaries · alzhub.org/study/lecanemab-binds-to-transgenic-mouse-modelderived-amyloid-fibril-40495448

   Our results show that lecanemab exhibits high binding affinity to amyloid-β fibril structures that have a flexible N-terminus in common, as is the case for type I, type II and murine type III amyloid-β fibril polymorphs, which …

7. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-clarity-ad-quality-of-life-results-from-a-randomized-double-37874099

   A total of 1795 participants were enrolled (lecanemab:898; placebo:897). At month 18, adjusted mean change from baseline in EQ-5D-5L and QOL-AD by subject showed 49% and 56% less decline, respectively. QOL-AD rated by study …

8. Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorieResearch summary

   Research summaries · alzhub.org/study/lecanemab-e-la-malattia-di-alzheimer-perusini-tra-speranze-40637522

   … developed and one of them (lecanemab) recently received marketing authorization by the European Medicines Agency (Ema). Although they represent an important innovation in the treatment of AD, their clinical net benefit is …

9. Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotesResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-treatment-of-individuals-with-early-alzheimer-s-disease-41689888

   … non-carriers (85 %). Lecanemab significantly reduced clinical decline on CDR-SB at 18 months compared to placebo in the ApoEε4 heterozygotes or non-carriers subgroup. Amyloid PET, ADAS-Cog14, ADCS-MCI-ADL, and HRQoL results were …

10. Lecanemab in clinical practice: real-world outcomes in early Alzheimer's diseaseResearch summary

    Research summaries · alzhub.org/study/lecanemab-in-clinical-practice-real-world-outcomes-in-early-alzheimer-40437535

    … screened and 86 initiated lecanemab treatment. In the intention-to-treat (ITT) population, MMSE scores declined significantly over 6 months (F(1, 45.13) = 7.41, p =.009). Subgroup analysis revealed a significant decline in …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28381 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-05. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.